A Phase 1 first time in human study to evaluate the safety, pharmacokinetics and immunogenicity of MEDI5083 alone and in combination with durvalumab in select advanced solid tumors February 15, 2018 Type of Cancer Solid Tumor Sponsor Medimmune Protocol Number D6840C00001 To Learn More Call (201)-510-0950
